May 11 became a turning point of Altimmune stock to keep increasing until the current price of over $6. Since the announcement of the novel single-dose intranasal vaccine on the 28th of February the biopharmaceutical company has been testing and developing it to use in the real-world battle against the COVID-19. It is not fully prepared yet and even Q1 2020 earnings are negative because of a significant decrease in revenue and an increase in its cost. Moreover, Q1 common stock equity decreased to $41.897.000 from Q4 2019’s $45.520.000.
Altimmune’s COVID-19 related goal could be achieved soon, meanwhile, its stock soars by giving hope to new stockholders who have long term plans.
Editor in Chief.
Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life